PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31959479-1	2020	BACKGROUND: Daclatasvir (DCV) is a HCV NS5A inhibitor whose plasma exposure may be influenced by co-administration with inducers or inhibitors of CYP3A4 such as many antiretrovirals.	daclatasvir	12-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152	
31959479-1	2020	BACKGROUND: Daclatasvir (DCV) is a HCV NS5A inhibitor whose plasma exposure may be influenced by co-administration with inducers or inhibitors of CYP3A4 such as many antiretrovirals.	daclatasvir	25-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152	
31645655-1	2020	Direct-acting antivirals, asunaprevir (ASV), daclatasvir (DCV), and beclabuvir (BCV) are known to be mainly metabolized by CYP3A enzymes; however, the differences in the detailed metabolic activities of CYP3A4 and CYP3A5 on these drugs are not well clarified.	daclatasvir	45-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	203-209	
31645655-1	2020	Direct-acting antivirals, asunaprevir (ASV), daclatasvir (DCV), and beclabuvir (BCV) are known to be mainly metabolized by CYP3A enzymes; however, the differences in the detailed metabolic activities of CYP3A4 and CYP3A5 on these drugs are not well clarified.	daclatasvir	58-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	203-209	
31645655-2	2020	The aim of the present study was to elucidate the relative contributions of CYP3A4 and CYP3A5 to the metabolism of ASV, DCV, and BCV, as well as the effect of CYP3A5*3 genetic variant in vitro.	daclatasvir	120-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82	
31291311-9	2019	CONCLUSIONS: CYP3A4 rs4646437 was found to be significantly and independently associated with ALT elevation in Japanese patients receiving ASV plus DCV therapy.	daclatasvir	148-151	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19	
27530469-7	2017	DDI are more likely to occur with 3D regimen, daclatasvir, simeprevir and ledipasvir, as they are all both substrates and inhibitors of P-gp and/or CYP3A4, than with sofosbuvir.	daclatasvir	46-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	148-154	
27798211-2	2017	When combined with the CYP3A4 substrate daclatasvir, the daclatasvir dosage should be reduced from 60 to 30 mg once daily.	daclatasvir	57-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29	
27664109-4	2016	DCV may be the object of a DDI via the induction or inhibition of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) by the concomitant medication, or the precipitant of a DDI via DCV-based induction/inhibition of CYP 3A4 or inhibition of P-gp, organic anion transporting polypeptide 1B1/B3, and/or breast cancer resistance protein.	daclatasvir	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-91	
27664109-4	2016	DCV may be the object of a DDI via the induction or inhibition of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) by the concomitant medication, or the precipitant of a DDI via DCV-based induction/inhibition of CYP 3A4 or inhibition of P-gp, organic anion transporting polypeptide 1B1/B3, and/or breast cancer resistance protein.	daclatasvir	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	218-225	
29353349-8	2018	Daclatasvir has low-to-moderate clearance with the predominant route of elimination via cytochrome P450 3A4-mediated metabolism and P-glycoprotein excretion and intestinal secretion.	daclatasvir	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-107	
29353349-10	2018	As a result, the dose of daclatasvir should be reduced from 60 to 30 mg once daily when co-administered with strong inhibitors of cytochrome P450 3A4.	daclatasvir	25-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	130-149	
29353349-12	2018	The dose of daclatasvir should be increased from 60 to 90 mg once daily when co-administered with moderate inducers of cytochrome P450 3A4.	daclatasvir	12-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-138	
29353349-13	2018	Co-administration of daclatasvir with strong inducers of cytochrome P450 3A4 is contraindicated.	daclatasvir	21-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-76	
26744738-8	2015	Daclatasvir and asunaprevir are substrates for cytochrome P450 3A4 enzymatic pathway; thus, there is a substantial potential for drug interactions.	daclatasvir	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-66